OKYO Pharma to join BTIG Biotech Conference 2026

OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, reports that senior management will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026.

Rhea-AI Filing Summary

OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, reports that senior management will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026.

The chief executive officer, chief financial officer and chief medical officer will be available for one-on-one meetings. The company also states that it plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain. This report is incorporated by reference into OKYO Pharma’s Registration Statement on Form F-3 (No. 333-293145).

Key Figures

Conference dates: July 28-29, 2026 Planned Phase 3 enrollment: approximately 111 patients Form F-3 registration number: 333-293145

3 metrics

Conference dates July 28-29, 2026 Timing of the BTIG Biotechnology Conference 2026, held virtually

Planned Phase 3 enrollment approximately 111 patients Planned enrollment for global Phase 3 pivotal trial of urcosimod in neuropathic corneal pain

Form F-3 registration number 333-293145 Registration Statement on Form F-3 into which this report is incorporated by reference

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, Phase 3 pivotal clinical trial, single-dose regimen

4 terms

neuropathic corneal pain (NCP) medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OKYO Pharma (OKYO) announce regarding the BTIG Biotechnology Conference 2026?

OKYO Pharma announced that its senior management will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. The CEO, CFO and CMO will attend and be available for one-on-one meetings arranged through BTIG representatives.

Who will represent OKYO Pharma (OKYO) at the BTIG Biotechnology Conference 2026?

OKYO Pharma will be represented by Robert J. Dempsey (Chief Executive Officer), Keeren Shah (Chief Financial Officer) and Flavio Mantelli MD, PhD (Chief Medical Officer). These executives will participate in the conference and be available for virtual one-on-one investor meetings.

What clinical development plan did OKYO Pharma (OKYO) highlight in this report?

OKYO Pharma stated that it plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year. The trial will enroll approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain.

What indication is OKYO Pharma (OKYO) targeting with urcosimod?

OKYO Pharma is developing urcosimod for the treatment of neuropathic corneal pain (NCP). The planned global Phase 3 pivotal trial will assess a single-dose regimen of urcosimod in about 111 patients suffering from this eye pain condition.

On which market are OKYO Pharma (OKYO) shares listed?

OKYO Pharma’s ordinary shares are listed for trading on the Nasdaq Capital Market. The company describes itself as a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and anterior segment eye diseases.

How is this OKYO Pharma (OKYO) report linked to its existing registration statement?

The report is incorporated by reference into OKYO Pharma’s Registration Statement on Form F-3 (Reg. No. 333-293145). This means the information furnished here becomes part of that existing shelf registration framework for securities offerings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 07:00 AM Accepted by SEC EDGAR 07/27/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 27, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 27, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 27, 2026

4

Exhibit 99.1

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

London and New York, NY, July 27, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.

Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: July 28-29, 2026

Location: Virtual

1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 7.2 KB
• EX-99 GRAPHIC 4.4 KB